Sez6l2 regulates phosphorylation of ADD and neuritogenesis

Hiroaki Yaguchi, Ichiro Yabe, Hidehisa Takahashi, Masashi Watanabe, Taichi Nomura, Takahiro Kano, Masaki Matsumoto, Keiichi I. Nakayama, Masahiko Watanabe, Shigetsugu Hatakeyama

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抄録

Increasing evidence shows that immune-mediated mechanisms may contribute to the pathogenesis of central nervous system disorders including cerebellar ataxias, as indicated by the aberrant production of neuronal surface antibodies. We previously reported a patient with cerebellar ataxia associated with production of a new anti-neuronal antibody, anti-seizure-related 6 homolog like 2 (Sez6l2). Sez6l2 is a type 1 membrane protein that is highly expressed in the hippocampus and cerebellar cortex and mice lacking Sez6l2 protein family members develop ataxia. Here we used a proteomics-based approach to show that serum derived from this patient recognizes the extracellular domain of Sez6l2 and that Sez6l2 protein binds to both adducin (ADD) and glutamate receptor 1 (GluR1). Our results indicate that Sez6l2 is one of the auxiliary subunits of the AMPA receptor and acts as a scaffolding protein to link GluR1 to ADD. Furthermore, Sez6l2 overexpression upregulates ADD phosphorylation, whereas siRNA-mediated downregulation of Sez612 prevents ADD phosphorylation, suggesting that Sez6l2 modulates AMPA-ADD signal transduction.

元の言語英語
ページ(範囲)234-241
ページ数8
ジャーナルBiochemical and Biophysical Research Communications
494
発行部数1-2
DOI
出版物ステータス出版済み - 12 9 2017

Fingerprint

Phosphorylation
Seizures
Glutamate Receptors
Cerebellar Ataxia
Signal transduction
Proteins
AMPA Receptors
Neurology
Small Interfering RNA
Anti-Idiotypic Antibodies
Membrane Proteins
Cerebellar Cortex
adducin
Central Nervous System Diseases
Ataxia
Proteomics
Antibodies
Signal Transduction
Hippocampus
Up-Regulation

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

これを引用

Yaguchi, H., Yabe, I., Takahashi, H., Watanabe, M., Nomura, T., Kano, T., ... Hatakeyama, S. (2017). Sez6l2 regulates phosphorylation of ADD and neuritogenesis. Biochemical and Biophysical Research Communications, 494(1-2), 234-241. https://doi.org/10.1016/j.bbrc.2017.10.047

Sez6l2 regulates phosphorylation of ADD and neuritogenesis. / Yaguchi, Hiroaki; Yabe, Ichiro; Takahashi, Hidehisa; Watanabe, Masashi; Nomura, Taichi; Kano, Takahiro; Matsumoto, Masaki; Nakayama, Keiichi I.; Watanabe, Masahiko; Hatakeyama, Shigetsugu.

:: Biochemical and Biophysical Research Communications, 巻 494, 番号 1-2, 09.12.2017, p. 234-241.

研究成果: ジャーナルへの寄稿記事

Yaguchi, H, Yabe, I, Takahashi, H, Watanabe, M, Nomura, T, Kano, T, Matsumoto, M, Nakayama, KI, Watanabe, M & Hatakeyama, S 2017, 'Sez6l2 regulates phosphorylation of ADD and neuritogenesis', Biochemical and Biophysical Research Communications, 巻. 494, 番号 1-2, pp. 234-241. https://doi.org/10.1016/j.bbrc.2017.10.047
Yaguchi H, Yabe I, Takahashi H, Watanabe M, Nomura T, Kano T その他. Sez6l2 regulates phosphorylation of ADD and neuritogenesis. Biochemical and Biophysical Research Communications. 2017 12 9;494(1-2):234-241. https://doi.org/10.1016/j.bbrc.2017.10.047
Yaguchi, Hiroaki ; Yabe, Ichiro ; Takahashi, Hidehisa ; Watanabe, Masashi ; Nomura, Taichi ; Kano, Takahiro ; Matsumoto, Masaki ; Nakayama, Keiichi I. ; Watanabe, Masahiko ; Hatakeyama, Shigetsugu. / Sez6l2 regulates phosphorylation of ADD and neuritogenesis. :: Biochemical and Biophysical Research Communications. 2017 ; 巻 494, 番号 1-2. pp. 234-241.
@article{fef8ef3d441047cb90f87e8dcf2c3052,
title = "Sez6l2 regulates phosphorylation of ADD and neuritogenesis",
abstract = "Increasing evidence shows that immune-mediated mechanisms may contribute to the pathogenesis of central nervous system disorders including cerebellar ataxias, as indicated by the aberrant production of neuronal surface antibodies. We previously reported a patient with cerebellar ataxia associated with production of a new anti-neuronal antibody, anti-seizure-related 6 homolog like 2 (Sez6l2). Sez6l2 is a type 1 membrane protein that is highly expressed in the hippocampus and cerebellar cortex and mice lacking Sez6l2 protein family members develop ataxia. Here we used a proteomics-based approach to show that serum derived from this patient recognizes the extracellular domain of Sez6l2 and that Sez6l2 protein binds to both adducin (ADD) and glutamate receptor 1 (GluR1). Our results indicate that Sez6l2 is one of the auxiliary subunits of the AMPA receptor and acts as a scaffolding protein to link GluR1 to ADD. Furthermore, Sez6l2 overexpression upregulates ADD phosphorylation, whereas siRNA-mediated downregulation of Sez612 prevents ADD phosphorylation, suggesting that Sez6l2 modulates AMPA-ADD signal transduction.",
author = "Hiroaki Yaguchi and Ichiro Yabe and Hidehisa Takahashi and Masashi Watanabe and Taichi Nomura and Takahiro Kano and Masaki Matsumoto and Nakayama, {Keiichi I.} and Masahiko Watanabe and Shigetsugu Hatakeyama",
year = "2017",
month = "12",
day = "9",
doi = "10.1016/j.bbrc.2017.10.047",
language = "English",
volume = "494",
pages = "234--241",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1-2",

}

TY - JOUR

T1 - Sez6l2 regulates phosphorylation of ADD and neuritogenesis

AU - Yaguchi, Hiroaki

AU - Yabe, Ichiro

AU - Takahashi, Hidehisa

AU - Watanabe, Masashi

AU - Nomura, Taichi

AU - Kano, Takahiro

AU - Matsumoto, Masaki

AU - Nakayama, Keiichi I.

AU - Watanabe, Masahiko

AU - Hatakeyama, Shigetsugu

PY - 2017/12/9

Y1 - 2017/12/9

N2 - Increasing evidence shows that immune-mediated mechanisms may contribute to the pathogenesis of central nervous system disorders including cerebellar ataxias, as indicated by the aberrant production of neuronal surface antibodies. We previously reported a patient with cerebellar ataxia associated with production of a new anti-neuronal antibody, anti-seizure-related 6 homolog like 2 (Sez6l2). Sez6l2 is a type 1 membrane protein that is highly expressed in the hippocampus and cerebellar cortex and mice lacking Sez6l2 protein family members develop ataxia. Here we used a proteomics-based approach to show that serum derived from this patient recognizes the extracellular domain of Sez6l2 and that Sez6l2 protein binds to both adducin (ADD) and glutamate receptor 1 (GluR1). Our results indicate that Sez6l2 is one of the auxiliary subunits of the AMPA receptor and acts as a scaffolding protein to link GluR1 to ADD. Furthermore, Sez6l2 overexpression upregulates ADD phosphorylation, whereas siRNA-mediated downregulation of Sez612 prevents ADD phosphorylation, suggesting that Sez6l2 modulates AMPA-ADD signal transduction.

AB - Increasing evidence shows that immune-mediated mechanisms may contribute to the pathogenesis of central nervous system disorders including cerebellar ataxias, as indicated by the aberrant production of neuronal surface antibodies. We previously reported a patient with cerebellar ataxia associated with production of a new anti-neuronal antibody, anti-seizure-related 6 homolog like 2 (Sez6l2). Sez6l2 is a type 1 membrane protein that is highly expressed in the hippocampus and cerebellar cortex and mice lacking Sez6l2 protein family members develop ataxia. Here we used a proteomics-based approach to show that serum derived from this patient recognizes the extracellular domain of Sez6l2 and that Sez6l2 protein binds to both adducin (ADD) and glutamate receptor 1 (GluR1). Our results indicate that Sez6l2 is one of the auxiliary subunits of the AMPA receptor and acts as a scaffolding protein to link GluR1 to ADD. Furthermore, Sez6l2 overexpression upregulates ADD phosphorylation, whereas siRNA-mediated downregulation of Sez612 prevents ADD phosphorylation, suggesting that Sez6l2 modulates AMPA-ADD signal transduction.

UR - http://www.scopus.com/inward/record.url?scp=85031401204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031401204&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2017.10.047

DO - 10.1016/j.bbrc.2017.10.047

M3 - Article

C2 - 29032200

AN - SCOPUS:85031401204

VL - 494

SP - 234

EP - 241

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1-2

ER -